Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system
US8067247B2 · kind B2 · utility
22Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 2, 2004 |
| Grant date | Nov 29, 2011 |
| Priority date | — |
| Expiry date | Dec 10, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.